ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 279 entries already.
Professor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
Ariane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based CDMO/CRO.
Swedish life science company PeptiSystems has appointed Ida Nordberg as Chief Financial Officer (CFO). The appointment marks another milestone in the company’s development and further strengthens the organization as it enters its next phase of commercialization and international expansion
SLAS Europe 2026 in Vienna brought together over 1,500 delegates for three days of innovation and collaboration. As we look ahead, join us at upcoming Meet-Ups in Leiden and Tübingen, and mark your calendars for SLAS2027 in San Diego, California.
With the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development of its lead candidate for diabetic eye disease.
Drug discovery depends on more than breakthrough science alone. Progress increasingly emerges from connected ecosystems where academia, biotech, pharma, CROs and technology providers can openly exchange ideas, challenge assumptions and accelerate innovation together.
See-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.
European biotech is seeing both encouraging momentum and challenges. Innovation from European academia continues to inspire therapeutic concepts.
CM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices